THE 13th SUGIYAMA LABORATORY (RIKEN) OPEN SYMPOSIUM

“New challenges for in vitro and in vivo extrapolations with regard to DDI and clearance estimation; Albumin effect and critical scaling factors”

Date : 13:00 - 17:35, February 22nd, 2019
Venue : RIKEN Yokohama Main Office Building Hall

13:00-13:05 Opening remarks
Yuichi Sugiyama (Sugiyama Laboratory, RIKEN)

13:05-14:00 【Plenary lecture】
Visomedigib and Venetoclax: Approved Drugs with Unique Pharmacokinetic Properties
Cornelis “Marcel” Hop (Genentech inc.)

14:00-14:35 Development of Orthogonal Linear Separation Analysis (OLSA) to Decompose Pharmacological Effect and Extract Elementary Ones
Hiroyuki Kusuhara (The University of Tokyo / RIKEN)

14:35-15:05 PBPK model of rifampicin as a perpetrator integrating bottom-up and top-down approaches
Ryuta Asaumi (Ono Pharmaceutical Co., Ltd.)

15:05-15:25 Coffee break

15:25-15:55 Analysis of drug - drug interactions of pitavastatin and rosuvastatin with oral or intravenous administration of rifampicin using PBPK models.
Mayuko Miyagawa (Astellas Pharma Inc.)

15:55-16:25 Application of PBPK modeling to renal OCT2 and MATEs mediated DDIs: Predicting changes in renal clearance and blood AUC caused by the transporter inhibitors.
Kotaro Nishiyama (Nippon Boehringer Ingelheim Co., Ltd.)

16:25-16:55 In vitro and in vivo extrapolation of hepatic uptake clearances for drugs with high protein binding accounted for the "albumin mediated" hepatic uptake mechanism.
Seiji Miyauchi (Toho University / RIKEN)

16:55-17:35 General Discussion
Yuichi Sugiyama (Sugiyama Laboratory, RIKEN)

17:45-19:20 Banquet (Cafeteria at Yokohama RIKEN)

[This Symposium is a part of the RIKEN Symposium Series.]